BPC-157+TB-500:10MG Blend (Inj)

A fixed-ratio co-formulation of BPC-157 and TB-500 in a single vial, sold as the Wolverine Stack. Standard presentation is 5 mg BPC-157 + 5 mg TB-500, 10 mg total peptide; a larger 10 mg + 10 mg (20 mg total) presentation also circulates. The 1:1 weight ratio delivers both arms at commonly used therapeutic doses at standard injection volumes.

BPC-157 arm: a synthetic 15-amino-acid pentadecapeptide derived from a cytoprotective protein isolated from human gastric juice. It acts through growth factor signalling, nitric oxide modulation and angiogenesis, with predominantly localised tissue repair activity.

TB-500 arm: a synthetic version of thymosin beta-4, a 43-amino-acid protein present in nearly every human and animal cell. It acts through actin regulation, cell migration and systemic tissue regeneration.

The rationale for the pairing is mechanistic non-overlap rather than potency: local angiogenic and growth-factor signalling from one arm, systemic migratory and remodelling activity from the other. No controlled study has tested the combination head-to-head against either peptide alone.

The trade-off against separate vials is titration and placement. The blend escalates both arms together and forces a single injection site, whereas separate vials allow independent dose adjustment, different cycle lengths, and site-specific BPC-157 with abdominal TB-500.

Regulatory position: not FDA approved for human use; both peptides are WADA-prohibited under the S0 Unapproved Substances category; both were classified as FDA Category 2 bulk drug substances in 2023, effectively barring compounded use on insufficient human safety evidence; both are banned by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA. Neither is legal for sale as a drug, food or dietary supplement in the US.

The combination rationale is stage coverage across the repair cascade — inflammation control, angiogenesis, cell migration, tissue rebuilding, remodelling — with each arm specialising in different stages.

BPC-157 creates the conditions for repair. It upregulates VEGFR2 expression, triggering angiogenesis through the Akt-eNOS signalling pathway, and modulates nitric oxide synthesis to dilate existing vessels and improve perfusion. It activates the FAK-paxillin pathway for local cell migration and anchoring, and upregulates growth hormone receptor expression in tendon fibroblasts, increasing their responsiveness to circulating GH. Critically, it amplifies existing repair signalling rather than initiating it, which is why damaged tissue is required for any effect. Half-life is under 30 minutes, so activity concentrates near the injection site before clearance.

TB-500 supplies the workforce. Its primary mechanism is actin sequestration — actin constitutes roughly 10% of total cellular protein content — holding monomers in reserve and transferring them to profilin on demand, driving the cytoskeletal reorganisation that permits repair cells to migrate. It promotes angiogenesis through a distinct route, acting on VEGF signalling and directly on endothelial cells. Metabolism releases the tetrapeptide Ac-SDKP, a potent anti-inflammatory and antifibrotic fragment that limits disorganised scar formation. It also mobilises stem cells and satellite cells. Low molecular weight and absence of extracellular matrix binding give free tissue distribution independent of injection site.

The complementary pairs are specific. Angiogenesis: BPC-157 upregulates the receptor while TB-500 stimulates the ligand and endothelium. Cell migration: FAK-paxillin for local attachment against actin regulation for long-range movement. Inflammation: BPC-157 reduces COX-2 expression and IL-6 and TNF-alpha, while Ac-SDKP suppresses inflammatory cytokine production and immune cell overactivation. Tissue quality: BPC-157 drives fibroblast activity and collagen production while TB-500 reduces myofibroblast activity, yielding more organised tissue. Coverage: localised plus systemic in one injection.

No controlled study has confirmed synergy. Lee and Padgett (2021), a retrospective chart review, included 4 patients receiving intraarticular BPC-157 plus thymosin beta-4 — too small to support any conclusion about combination superiority.

Tendon and ligament repair is the primary application. BPC-157 promotes tendon fibroblast outgrowth, cell survival and localised repair; TB-500 drives fibroblast migration into damaged connective tissue, improves the biomechanical properties of healing ligaments, and prevents adhesion and fibrous band formation. Typical targets: Achilles injuries, rotator cuff tears, patellar tendonitis, epicondylitis, ACL and MCL sprains.

Muscle: BPC-157 promotes fibre regeneration with improved structure and biomechanics in animal models; TB-500 acts as a chemoattractant for myoblasts.

Post-surgical: commonly used after ACL reconstruction, rotator cuff repair, meniscus surgery and general soft tissue procedures, on the rationale that surgical tissue benefits from the same cascade enhancement as traumatic injury. Surgeon approval first.

Joint support: ongoing anti-inflammatory activity from both arms via different pathways plus remodelling support, typically over a longer run than acute protocols.

Wound healing: BPC-157 contributes angiogenesis, re-epithelialisation and collagen deposition; TB-500 increased re-epithelialisation by 42% at day 4 and 61% at day 7 in rat models with reduced scar formation.

Gastrointestinal activity derives from the BPC-157 arm only, owing to its stability in gastric juice — ulcer healing, protection against NSAID-induced mucosal damage, and support in inflammatory bowel models. Oral BPC-157 alone may be the better route where the gut is the target tissue.

Additional BPC-157 effects: collagen synthesis with dermal thickness, elasticity and hair growth promotion; reduction of existing scar tissue when administered into the scarred region; bidirectional blood pressure normalisation through the NO system; elevated central dopamine and serotonin with analgesia and mood and memory support; increased bone density with reduced cartilage lesions and joint pain.

Route-dependent behaviour is the blend's distinguishing feature. BPC-157 concentrates near the injection site because of its sub-30-minute half-life; TB-500 distributes systemically regardless of site. Local injection therefore targets a single lesion while still providing body-wide coverage, and abdominal injection covers multiple simultaneous injuries at the cost of local BPC-157 concentration.

No published study has examined healing timelines for the BPC-157 + TB-500 combination in humans. The available data are individual-peptide findings plus one small combination group.

Lee and Padgett (2021): a retrospective chart review of 17 patients with chronic knee pain given intraarticular injections, 12 receiving BPC-157 alone and 4 receiving BPC-157 plus thymosin beta-4. Of the 16 contactable at follow-up, 14 (87.5%) reported significant pain relief lasting 6 months to 1 year after a single injection; 11 of 12 (91.6%) in the monotherapy group and 3 of 4 (75%) in the combination group. Small, retrospective, uncontrolled, with no standardised outcome measures — it supports neither superiority nor equivalence.

Pharmacokinetics: BPC-157 has a half-life under 30 minutes, is hepatically metabolised and renally excreted, and is detectable in urine up to 4 days. TB-500 pharmacokinetics after subcutaneous administration have not been published; the frequently cited 10-day half-life is not derived from any published pharmacokinetic study. Low molecular weight and systemic distribution support less frequent dosing than very short half-life peptides.

Anecdotal timelines from external forums and user reports, weaker evidence than published work:

Weeks 1 to 2 — reduction in pain and inflammation, usually the first signal. A subset report initial fatigue or mild flu-like symptoms in the first few days, attributed chiefly to the TB-500 arm and typically resolving within 24 to 48 hours.

Weeks 3 to 4 — meaningful functional improvement in tendon and ligament injuries, with previously painful or limited movements becoming available and range of motion improving.

Weeks 6 to 8 — peak response for most injury types.

Muscle injuries respond faster (2 to 4 weeks) than tendon injuries (4 to 8 weeks). Chronic or older injuries take 8 to 12 weeks with less predictable outcomes.

Non-response is documented. Reports include no benefit from 250 mcg twice daily for 4 weeks in MRI-confirmed shoulder degeneration, and descriptions of no difference from saline. Variability is highest in chronic, long-standing and degenerative presentations.

No published dose-finding study exists for the subcutaneous combination. Lee and Padgett (2021) used intraarticular injection and did not specify per-peptide doses in the combination group. Individual-peptide reference points: BPC-157 animal studies used 10 mcg/kg to 10 mg/kg intraperitoneally, subcutaneously or intragastrically, with human single doses up to 20 mg intravenous, 4000 mcg intraarticular and 10 mg intravesical; TB-500 human Phase I studies used intravenous doses from 42 mg to 1260 mg, with no published subcutaneous doses. The protocols below reflect practice patterns, not dose-finding research.

Standard presentation: 5 mg BPC-157 + 5 mg TB-500, 10 mg total, reconstituted with 2 mL bacteriostatic water for 250 mcg of each peptide per 10 units on an insulin syringe. Dose 250 to 500 mcg of each peptide once daily, 10 to 20 units, subcutaneous, any time of day, fasting not required, 4 to 8 weeks for active healing.

By body weight: under 150 lbs, 250 mcg daily of each; 150 to 200 lbs, 250 to 400 mcg daily of each; over 200 lbs, 400 to 500 mcg daily of each.

By application: acute strain, sprain or tear, 250 to 500 mcg daily for 4 to 6 weeks; post-surgical recovery, 250 to 500 mcg daily for 4 to 8 weeks with surgeon approval; chronic injury or joint support, 250 to 500 mcg daily for 6 to 8 weeks; multiple simultaneous injuries, 500 mcg daily for 6 to 8 weeks.

Site selection follows the pharmacokinetic asymmetry. A single lesion favours local injection, capturing BPC-157's localised concentration alongside systemic TB-500. Multiple lesions or convenience favours abdominal or thigh administration; BPC-157 still circulates, at lower concentration than a local injection. Abdominal injection is the most common choice in practice, and intramuscular administration is also used for faster absorption.

No cycling requirement exists — neither compound is hormonal. Standard runs are 4 to 8 weeks for acute injuries, extendable to 8 to 12 weeks for chronic or deeper tissue damage.

A 10 mg + 10 mg (20 mg total) presentation is also sold. With 2 mL it gives 100 mcg of blended peptide per unit; commonly run at 600 mcg daily for weeks 1 to 2 then 800 mcg for weeks 3 to 8, or 1,000 mcg daily for weeks 1 to 2 then 600 mcg for weeks 3 to 8, on an 8-week cycle with a 4 to 8 week washout.

Drawing from this vial and a growth hormone peptide vial into the same syringe is acceptable where timing aligns, but do not pre-mix and store, and do not combine with GLP-1 agonists in one syringe.

No controlled head-to-head study has compared the BPC-157 + TB-500 combination against either component alone. The rationale rests on non-overlapping mechanisms — VEGFR2 upregulation, Akt-eNOS angiogenesis, FAK-paxillin adhesion and growth hormone receptor upregulation in tendon fibroblasts from one arm; actin sequestration, profilin handoff, endothelial VEGF signalling, and Ac-SDKP-mediated anti-inflammatory and antifibrotic activity from the other.

Lee and Padgett (2021) is the only published dataset containing a combination arm: a retrospective chart review of 17 patients with chronic knee pain given intraarticular injections at the Institute for Hormonal Balance in Orlando, Florida. Twelve received BPC-157 alone, 4 received BPC-157 plus thymosin beta-4. Of 16 contactable at follow-up, 14 (87.5%) reported significant pain relief; 11 of 12 (91.6%) in the monotherapy group and 3 of 4 (75%) in the combination group. Retrospective, uncontrolled, no standardised outcome measures, n=4 in the arm of interest. Superiority, equivalence, and inferiority are all unresolvable from it.

BPC-157 supporting evidence: a 2025 HSS Journal systematic review of 36 studies — 35 preclinical, 1 clinical — confirming angiogenesis, fibroblast activation, and anti-inflammatory mechanisms with no acute toxicity across organ systems at doses up to 20 mg/kg in animals. A 2025 Current Reviews in Musculoskeletal Medicine narrative review reported inhibition of uncontrolled proliferation and downregulation of VEGF in tumour contexts in animal models. Human data comprise three small pilots: IV infusion up to 20 mg in 2 healthy adults with no adverse events, an interstitial cystitis study with complete symptom resolution in 10 of 12 women, and the knee study above.

TB-500 supporting evidence: Malinda et al. (1999) — re-epithelialisation up 42% at day 4 and 61% at day 7 in rats with improved contraction and collagen deposition. Ehrlich and Hazard (2010) — minimal scarring, preserved breaking strength, organised mature collagen. Xu et al. (2013) — improved biomechanics of healing medial collateral ligaments with more uniform fibre bundles and increased fibril diameter. Phase I safety from Ruff et al. (2010), IV up to 1260 mg, and Wang et al. (2021) in 84 volunteers, with no dose-limiting toxicities.

Preclinical depth, human shallowness, and no combination trial.